What is the correct dosing for Venofer (iron sucrose)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Venofer (Iron Sucrose) Dosing

The maximum single dose of Venofer is 200 mg, with a maximum weekly dose of 500 mg, administered either as a slow IV push over 2-5 minutes (FDA) or as an infusion over 15-30 minutes depending on regulatory guidance. 1, 2

Standard Dosing Parameters

Maximum Dose Limits

  • Single dose maximum: 200 mg elemental iron 1, 2
  • Weekly dose maximum: 500 mg elemental iron 1, 2
  • Concentration: 20 mg elemental iron per mL, available in 100 mg (5 mL) vials 2

Administration Methods

For Direct IV Injection (Slow IV Push):

  • Administer undiluted at 100 mg over 2-5 minutes per FDA guidelines 2
  • Doses of 100 mg minimize the risk of arthralgia-myalgia reactions 2

For IV Infusion:

  • Dilute in normal saline solution 2
  • FDA recommends 15 minutes for doses up to 200 mg 1, 2
  • European Medicines Agency recommends 30 minutes for doses up to 200 mg 1, 2
  • For doses of 300-500 mg, dilute in maximum 250 mL of 0.9% NaCl 3

Practical Dosing Strategy

Typical Maintenance Dosing

  • 100 mg per dose is the typical administration that minimizes adverse effects 2
  • This can be given weekly or as clinically indicated based on iron parameters 2

Higher Dose Regimens

  • 200 mg weekly for 5 doses has been studied and shown effective in CKD patients 4, 5
  • 250 mg monthly has been used successfully in stable hemodialysis patients on erythropoietin 6

Important Safety Considerations

Pre-Administration Requirements

  • Test doses are NOT required for iron sucrose 7
  • However, test doses are recommended for patients with history of sensitivities to IV iron or multiple drug allergies 3
  • Do not administer to patients with active infection 3
  • Ensure resuscitation facilities are available during administration 3

Monitoring During Administration

  • Monitor vital signs during and after infusion 3, 2
  • Watch for hypotension, flushing, abdominal cramps, and arthralgias/myalgias 3, 2

Dose-Related Adverse Effects

  • Arthralgias and myalgias are dose-related and rarely occur with doses ≤100 mg 2
  • Hypotension and flushing are rare 2
  • Abdominal cramps are rare, particularly when co-administered with ACE inhibitors 2

Clinical Monitoring Parameters

Laboratory Follow-Up

  • Monitor hemoglobin, ferritin, and transferrin saturation to assess response 2
  • Transferrin and ferritin levels can be measured reliably 48 hours after IV administration 7
  • Free iron may occur if 100 mg is administered when transferrin levels are <180 mg/dL 2

Management of Infusion Reactions

  • For minor reactions: stop infusion, switch to hydration fluid, and monitor 3
  • Most reactions are self-limiting and resolve spontaneously 3
  • After 15 minutes, rechallenge may be considered with careful monitoring 3
  • If symptoms persist or worsen after 15 minutes, consider IV hydrocortisone 3

Common Pitfalls to Avoid

  • Avoid exceeding 200 mg single dose to minimize arthralgia-myalgia reactions 1, 2
  • Do not exceed 500 mg weekly as per guideline recommendations 1
  • Avoid administration in patients with active infection 3
  • Do not assume test doses are required - iron sucrose carries no black-box warning and test doses are not mandatory 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Iron Sucrose Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Iron Sucrose Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001

Research

Iron sucrose: the oldest iron therapy becomes new.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.